The companies are also planning to test a modified form of Rituxan named ocrelizumab in relapsing-remitting multiple sclerosis.

• 这种药物的联合开发者们已经开始在更加严重的多发性硬化患者里开展了临床试验，主要是进行性的多发性硬化病人。